Xcout Intel
Herantis Pharma Oyj
Herantis Pharma Oyj is a clinical-stage biotechnology company that develops disease-modifying therapies to halt or reverse the progression of neurodegenerative diseases. The company focuses on researching and advancing innovative treatments, such as its lead drug candidate HER-096, to address significant unmet medical needs.
Subscribe to see Herantis Pharma Oyj’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Herantis Pharma Oyj at a glance
Herantis Pharma Oyj is a health care company headquartered in Finland. Xcout tracks 5 named people at Herantis Pharma Oyj, including Timo Veromaa (MD, PhD, eMBA, Chairman of the Board).
Herantis Pharma Oyj leadership
- Timo VeromaaMD, PhD, eMBA, Chairman of the Board
- Aki PrihtiBoard member
- Frans WuiteMD, MBA, Board Member
- Hilde FurbergMSc, Board Member
- Mats ThorénBoard member
Herantis Pharma Oyj competitors
A few of Herantis Pharma Oyj's closest competitors — see the full list of competitors and alternatives →
Headquartered in Clermont-Ferrand, France, Axoltis Pharma is a biotechnology company focused on developing novel therapeutic solutions to restore blood-brain barrier integrity and treat neurodegenerative diseases.
AlzeCure Pharma is a Swedish clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative diseases, particularly Alzheimer’s disease and related cognitive disorders. Its programs target disease mechanisms and symptoms, serving patients with serious central nervous system conditions through potential prescription medicines.
Neusignal Therapeutics, Inc. is a Tokyo-based company focused on commercializing early-stage drug discovery from Tohoku with the goal of defeating dementia.
H. Lundbeck is a global pharmaceutical company that focuses exclusively on researching, developing, and commercializing therapies for brain diseases such as neurology and psychiatry disorders. The company serves patients worldwide suffering from conditions like Alzheimer's disease, Parkinson's disease, migraine, depression, and schizophrenia.
Magnolia Neurosciences Corp is a New York City-based biotechnology company developing a new class of neuroprotective medicines. Operating out of the Alexandria Center for Life Science, the firm focuses on advancing innovative treatments for neurological conditions.
Cellestial Health is a privately held therapeutics development company spun out from the University of Cambridge in 2023 to create new treatments for Parkinson's disease and related conditions.
Get Herantis Pharma Oyj's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Herantis Pharma Oyj in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access